Proportion of type 2 diabetic dyslipidemia patients achieving the target LDL goal according to ADA 2010. These patients should be on stable dose of Lipid Lowering Drugs(LDL) for at least 3 months [clinicaltrials_resource:27e8282675598482edfafe6d6a498485]
clinicaltrials_vocabulary:primary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:primary-outcome]
Proportion of type 2 diabetic dyslipidemia patients achieving the target LDL goal according to ADA 2010. These patients should be on stable dose of Lipid Lowering Drugs(LDL) for at least 3 months [clinicaltrials_resource:27e8282675598482edfafe6d6a498485]
Bio2RDF identifier
27e8282675598482edfafe6d6a498485
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:27e8282675598482edfafe6d6a498485
measure [clinicaltrials_vocabulary:measure]
Proportion of type 2 diabetic ...... gs(LDL) for at least 3 months
identifier
clinicaltrials_resource:27e8282675598482edfafe6d6a498485
title
Proportion of type 2 diabetic ...... gs(LDL) for at least 3 months
@en
type
label
Proportion of type 2 diabetic ...... 8282675598482edfafe6d6a498485]
@en